Ladies and gentlemen, thank you for standing by and welcome to Pharma Holdings' Third Quarter 2017 Earnings Conference Call. [Operator Instructions] Now, I would like to hand the conference over to your speaker for the day, Ms. Diana Huang. Over to you ma'am.

Thank you, Operator. Good morning ladies and gentlemen, and good evening to those of you joining us from China. Welcome to China Pharma Holding's third quarter 2017 earnings conference call. I'm Diana Huang, the Company's Investor Relations manager. Speaking on the call today are China Pharma's President and CEO and Interim CFO, Ms. Zhilin Li; and Corporate Vice President, Mr. Sam Hsing. In addition, I will provide translation during the Q&A session of the call. I would like to remind our listeners that on this call, management's prepared remarks contain forward-looking statements, which are subject to risks and uncertainties and management may make additional forward-looking statements in response to your questions. Therefore, the Company claims the protection of the Safe Harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from those discussed today due to such risks as market and customer acceptance and demands for our products, our ability to market our product, the impact of competitive product and pricing, the ability to develop and launch new product on a timely basis, the regulatory environment including government regulation in the PRC, our ability to obtain the requisite regulatory approvals to commercialize our products, fluctuations in operating results including spending for R&D and sales and marketing activities, and other risks detailed from time-to-time in our filings with the SEC. In addition, any projections as to the Company's future performance represent management's estimates as of today, November 15, 2017. China Pharma assumes no obligation to update those projections in the future as market conditions change. Now, it is my pleasure to turn the call over to China Pharma's CEO and Interim CFO, Ms. Li to make her opening remarks in Chinese, which will be translated by Sam. Afterwards, Sam will continue translating Ms. Li’s detailed discussion of the Company's third quarter 2017 financial results.

Thank you, Diana, and good morning everyone. I would like to thank each of you for joining us today and for your continued support of China Pharma. Our performance in generating revenue in the third quarter of 2017 was similar to the same period last year and we increased gross margin slightly due to the better cost control. Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales through active participation in recent provincial market openings to receive new drug tender offers and through further research of the basic medical market. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy." I will now read the rest of Ms. Li's prepared remarks in English. Now I would like to review our third quarter 2017 financial results and our balance sheet information. Revenues were $3.2 million and $3.1 million for the three months ended September 30, 2017 and 2016 respectively. Gross profit was $0.4 million and $0.3 million for the three months ended September 30, 2017 and 2016, respectively. Our gross profit margin in the third quarter of 2017 was 13.3% compared to 11.2% in the same period 2016. Our selling expenses for the three months ended September 30, 2017 were $0.7 million, which accounted for 21.7% of the total revenue in the third quarter of 2017,compared to $1 million for the same period 2016, which accounted for 29.7% of the total revenue in the third quarter of 2016.…

On behalf of the entire China Pharma team, we would like to thank you for your interest in the Company and participation on this call. For any of you traveling to China, we always welcome and encourage any visitors from our shareholders, potential investors and analysts. This concludes China Pharma's third quarter 2017 earnings call.

Thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you all for your participation. You may all disconnect lines now. Thank you.